{"id":"NCT02042183","sponsor":"Sucampo Pharma Americas, LLC","briefTitle":"Lubiprostone in Children With Functional Constipation","officialTitle":"A Multicentre, Randomised, Placebo-controlled, Double-blinded Study of the Efficacy, Safety, and Pharmacokinetics of Lubiprostone in Paediatric Subjects Aged â‰¥ 6 Years to < 18 Years With Functional Constipation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12-13","primaryCompletion":"2016-07-27","completion":"2016-07-27","firstPosted":"2014-01-22","resultsPosted":"2020-07-21","lastUpdate":"2020-07-21"},"enrollment":606,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Constipation - Functional"],"interventions":[{"type":"DRUG","name":"Lubiprostone","otherNames":["Amitiza"]},{"type":"DRUG","name":"Placebo","otherNames":["Matching Placebo"]}],"arms":[{"label":"Lubiprostone","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Study to determine if children (6-17 years old) with functional constipation will respond to being treated with lubiprostone for 12 weeks.","primaryOutcome":{"measure":"Number of Participants Classified as Overall Responders at Week 12","timeFrame":"at Week 12","effectByArm":[{"arm":"Lubiprostone","deltaMin":76,"sd":null},{"arm":"Placebo","deltaMin":28,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1609"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":117,"countries":["United States","Belgium","Canada","France","Netherlands","Poland","United Kingdom"]},"refs":{"pmids":["33838349"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":400},"commonTop":["Nausea","Abdominal pain","Vomiting","Headache","Diarrhoea"]}}